{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:04:23Z","timestamp":1790913863539,"version":"4.1.0"},"reference-count":51,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,11,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>PIM serine\/threonine kinases are overexpressed, translocated, or amplified in multiple B-cell lymphoma types. We have explored the frequency and relevance of PIM expression in different B-cell lymphoma types and investigated whether PIM inhibition could be a rational therapeutic approach. Increased expression of PIM2 was detected in subsets of mantle cell lymphoma, diffuse large B-cell lymphoma (DLBLC), follicular lymphoma, marginal zone lymphoma-mucosa\u2013associated lymphoid tissue type, chronic lymphocytic leukemia, and nodal marginal zone lymphoma cases. Increased PIM2 protein expression was associated with an aggressive clinical course in activated B-like-DLBCL patients. Pharmacologic and genetic inhibition of PIM2 revealed p4E-BP1(Thr37\/46) and p4E-BP1(Ser65) as molecular biomarkers characteristic of PIM2 activity and indicated the involvement of PIM2 kinase in regulating mammalian target of rapamycin complex 1. The simultaneous genetic inhibition of all 3 PIM kinases induced changes in apoptosis and cell cycle. In conclusion, we show that PIM2 kinase inhibition is a rational approach in DLBCL treatment, identify appropriate biomarkers for pharmacodynamic studies, and provide a new marker for patient stratification.<\/jats:p>","DOI":"10.1182\/blood-2011-03-344374","type":"journal-article","created":{"date-parts":[[2011,9,22]],"date-time":"2011-09-22T04:58:32Z","timestamp":1316667512000},"page":"5517-5527","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":93,"title":["PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma"],"prefix":"10.1182","volume":"118","author":[{"given":"Cristina","family":"G\u00f3mez-Abad","sequence":"first","affiliation":[{"name":"Molecular Pathology Programme, Lymphoma Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Pisonero","sequence":"additional","affiliation":[{"name":"Molecular Pathology Programme, Lymphoma Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;"},{"name":"Hospital Universitario Marques de Valdecilla\/Instituto de formaci\u00f3n e investigaci\u00f3n Marqu\u00e9s de Valdecilla, Santander, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Blanco-Aparicio","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Programme and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Roncador","sequence":"additional","affiliation":[{"name":"Monoclonal Antibodies Unit, Biotechnology Programme, CNIO, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Gonz\u00e1lez-Mench\u00e9n","sequence":"additional","affiliation":[{"name":"Hospital Reina Sof\u00eda, C\u00f3rdoba, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Martinez-Climent","sequence":"additional","affiliation":[{"name":"Oncology Division, Centro de investigaci\u00f3n m\u00e9dica aplicada Foundation for Applied Medical Research, Pamplona, Navarra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mata","sequence":"additional","affiliation":[{"name":"Molecular Pathology Programme, Lymphoma Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Elena","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Molecular Pathology Programme, Lymphoma Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Mu\u00f1oz-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Molecular Pathology Programme, Lymphoma Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"S\u00e1nchez-Beato","sequence":"additional","affiliation":[{"name":"Molecular Pathology Programme, Lymphoma Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Leal","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Programme and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Bischoff","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Programme and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Piris","sequence":"additional","affiliation":[{"name":"Molecular Pathology Programme, Lymphoma Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;"},{"name":"Hospital Universitario Marques de Valdecilla\/Instituto de formaci\u00f3n e investigaci\u00f3n Marqu\u00e9s de Valdecilla, Santander, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111808061449900_B1","volume":"Vol. 2","author":"Swerdlow","year":"2008","journal-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues"},{"issue":"11","key":"2019111808061449900_B2","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-10-2573","article-title":"Accurate classification of diffuse large b cell lymphoma into germinal center and activated b cell subtypes using a nuclease protection assay on paraffin embedded tissues.","volume":"17","author":"Rimsza","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6769","key":"2019111808061449900_B3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"1","key":"2019111808061449900_B4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1309\/AJCPJX4BJV9NLQHY","article-title":"The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.","volume":"135","author":"Meyer","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"17","key":"2019111808061449900_B5","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111808061449900_B6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.5858\/2009-0463-RSR.1","article-title":"Primary mediastinal (thymic) large B-cell lymphoma: a short review with brief discussion of mediastinal gray zone lymphoma.","volume":"135","author":"Hutchinson","year":"2011","journal-title":"Arch Pathol Lab Med"},{"issue":"26","key":"2019111808061449900_B7","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1200\/JCO.2005.05.015","article-title":"State-of-the-art therapeutics: diffuse large B-cell lymphoma.","volume":"23","author":"Coiffier","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111808061449900_B8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111808061449900_B9","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMra0807082","article-title":"Aggressive lymphomas.","volume":"362","author":"Lenz","year":"2010","journal-title":"N Engl J Med"},{"issue":"46","key":"2019111808061449900_B10","doi-asserted-by":"crossref","first-page":"45358","DOI":"10.1074\/jbc.M307933200","article-title":"The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death.","volume":"278","author":"Yan","year":"2003","journal-title":"J Biol Chem"},{"issue":"1-3","key":"2019111808061449900_B11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.febslet.2004.06.050","article-title":"Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site.","volume":"571","author":"Aho","year":"2004","journal-title":"FEBS Lett"},{"issue":"1","key":"2019111808061449900_B12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-4889(02)00347-6","article-title":"Phosphorylation of the cell cycle inhibitor p21Cip1\/WAF1 by Pim-1 kinase.","volume":"1593","author":"Wang","year":"2002","journal-title":"Biochim Biophys Acta"},{"issue":"13","key":"2019111808061449900_B13","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/0008-5472.CAN-08-0634","article-title":"Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.","volume":"68","author":"Morishita","year":"2008","journal-title":"Cancer Res"},{"issue":"1-2","key":"2019111808061449900_B14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1385\/ENDO:20:1-2:123","article-title":"Prolactin-regulated pim-1 transcription: identification of critical promoter elements and Akt signaling.","volume":"20","author":"Krishnan","year":"2003","journal-title":"Endocrine"},{"issue":"4","key":"2019111808061449900_B15","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/blood-2009-07-233445","article-title":"A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia\/lymphoma.","volume":"115","author":"Lin","year":"2010","journal-title":"Blood"},{"issue":"26","key":"2019111808061449900_B16","doi-asserted-by":"crossref","first-page":"18012","DOI":"10.1074\/jbc.M709695200","article-title":"Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma.","volume":"283","author":"Hogan","year":"2008","journal-title":"J Biol Chem"},{"issue":"6","key":"2019111808061449900_B17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S1074-7613(00)80145-4","article-title":"Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis.","volume":"11","author":"Shirogane","year":"1999","journal-title":"Immunity"},{"issue":"6","key":"2019111808061449900_B18","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3324\/haematol.2009.017079","article-title":"PIM serine\/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.","volume":"95","author":"Brault","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"2019111808061449900_B19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/0092-8674(89)90589-8","article-title":"Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors.","volume":"56","author":"van Lohuizen","year":"1989","journal-title":"Cell"},{"issue":"11","key":"2019111808061449900_B20","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1002\/j.1460-2075.1995.tb07251.x","article-title":"Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2.","volume":"14","author":"van der Lugt","year":"1995","journal-title":"EMBO J"},{"issue":"11","key":"2019111808061449900_B21","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1080\/10428190802419640","article-title":"Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.","volume":"49","author":"Hsi","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111808061449900_B22","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/10428190310001641251","article-title":"Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma.","volume":"45","author":"Cohen","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"6844","key":"2019111808061449900_B23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/35085588","article-title":"Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas.","volume":"412","author":"Pasqualucci","year":"2001","journal-title":"Nature"},{"issue":"22","key":"2019111808061449900_B24","doi-asserted-by":"crossref","first-page":"8857","DOI":"10.1073\/pnas.86.22.8857","article-title":"The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias.","volume":"86","author":"Amson","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2019111808061449900_B25","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2002-01-0008","article-title":"A molecular compendium of genes expressed in multiple myeloma.","volume":"100","author":"Claudio","year":"2002","journal-title":"Blood"},{"issue":"8","key":"2019111808061449900_B26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1158\/1541-7786.MCR-05-0007","article-title":"Pim family kinases enhance tumor growth of prostate cancer cells.","volume":"3","author":"Chen","year":"2005","journal-title":"Mol Cancer Res"},{"issue":"9","key":"2019111808061449900_B27","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.4161\/cbt.7.9.6418","article-title":"Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma.","volume":"7","author":"Reiser-Erkan","year":"2008","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"2019111808061449900_B28","first-page":"1405","article-title":"Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma.","volume":"91","author":"Rossi","year":"2006","journal-title":"Haematologica"},{"issue":"20","key":"2019111808061449900_B29","doi-asserted-by":"crossref","first-page":"6369","DOI":"10.1021\/jm901018f","article-title":"Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.","volume":"52","author":"Aku\u00e9-G\u00e9du","year":"2009","journal-title":"J Med Chem"},{"issue":"6","key":"2019111808061449900_B30","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1158\/1535-7163.MCT-08-1037","article-title":"Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells.","volume":"8","author":"Beharry","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"2019111808061449900_B31","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1016\/j.bmcl.2009.04.061","article-title":"Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.","volume":"19","author":"Grey","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"2019111808061449900_B32","first-page":"362","article-title":"PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.","volume":"119","author":"Hu","year":"2009","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111808061449900_B33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1021\/jm800937p","article-title":"Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.","volume":"52","author":"Xia","year":"2009","journal-title":"J Med Chem"},{"issue":"2","key":"2019111808061449900_B34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/13543770903496442","article-title":"Pim kinase inhibitors: a survey of the patent literature.","volume":"20","author":"Morwick","year":"2010","journal-title":"Expert Opin Ther Pat"},{"issue":"10","key":"2019111808061449900_B35","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1080\/10428190903189035","article-title":"Functional signatures identified in B-cell non-Hodgkin lymphoma profiles.","volume":"50","author":"Aggarwal","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"2019111808061449900_B36","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan E","year":"1958","journal-title":"Am Stat Assoc J"},{"issue":"5","key":"2019111808061449900_B37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111808061449900_B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.","volume":"35","author":"Peto","year":"1977","journal-title":"Br J Cancer"},{"issue":"15","key":"2019111808061449900_B39","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1101\/gad.1105003","article-title":"The serine\/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor.","volume":"17","author":"Fox","year":"2003","journal-title":"Genes Dev"},{"issue":"4","key":"2019111808061449900_B40","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3324\/haematol.2009.013870","article-title":"Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.","volume":"95","author":"Wozniak","year":"2010","journal-title":"Haematologica"},{"issue":"50","key":"2019111808061449900_B41","doi-asserted-by":"crossref","first-page":"41675","DOI":"10.1074\/jbc.M510711200","article-title":"Structure and substrate specificity of the Pim-1 kinase.","volume":"280","author":"Bullock","year":"2005","journal-title":"J Biol Chem"},{"issue":"10","key":"2019111808061449900_B42","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1172\/JCI26273","article-title":"The survival kinases Akt and Pim as potential pharmacological targets.","volume":"115","author":"Amaravadi","year":"2005","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111808061449900_B43","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/ng950","article-title":"High-throughput retroviral tagging to identify components of specific signaling pathways in cancer.","volume":"32","author":"Mikkers","year":"2002","journal-title":"Nat Genet"},{"issue":"12","key":"2019111808061449900_B44","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/nm1671","article-title":"Pim-1 regulates cardiomyocyte survival downstream of Akt.","volume":"13","author":"Muraski","year":"2007","journal-title":"Nat Med"},{"issue":"4","key":"2019111808061449900_B45","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.biocel.2004.11.005","article-title":"The serine\/threonine kinase Pim-1.","volume":"37","author":"Bachmann","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"issue":"13","key":"2019111808061449900_B46","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1128\/MCB.24.13.6104-6115.2004","article-title":"Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors.","volume":"24","author":"Mikkers","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"3","key":"2019111808061449900_B47","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.biocel.2005.10.010","article-title":"The oncogenic serine\/threonine kinase Pim-1 directly phosphorylates and activates the G2\/M specific phosphatase Cdc25C.","volume":"38","author":"Bachmann","year":"2006","journal-title":"Int J Biochem Cell Biol"},{"issue":"46","key":"2019111808061449900_B48","doi-asserted-by":"crossref","first-page":"48319","DOI":"10.1074\/jbc.M404440200","article-title":"The oncogenic serine\/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2\/M cell cycle checkpoint.","volume":"279","author":"Bachmann","year":"2004","journal-title":"J Biol Chem"},{"issue":"22","key":"2019111808061449900_B49","doi-asserted-by":"crossref","first-page":"8341","DOI":"10.1158\/0008-5472.CAN-04-2284","article-title":"Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation.","volume":"64","author":"Hammerman","year":"2004","journal-title":"Cancer Res"},{"issue":"2","key":"2019111808061449900_B50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.canlet.2010.09.016","article-title":"Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.","volume":"300","author":"Blanco-Aparicio","year":"2011","journal-title":"Cancer Lett"},{"issue":"7","key":"2019111808061449900_B51","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","article-title":"Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.","volume":"111","author":"Lam","year":"2008","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/20\/5517\/1346406\/zh804611005517.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/20\/5517\/1346406\/zh804611005517.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T01:54:12Z","timestamp":1638755652000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/20\/5517\/29775\/PIM2-inhibition-as-a-rational-therapeutic-approach"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,17]]},"references-count":51,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2011,11,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-03-344374","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,17]]}}}